Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 11/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15415179 | 0.86 | OPRM1 (0.37) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL20565295 | 0.86 | OPRM1 (0.44) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL15578068 | 0.86 | OPRM1 (0.39) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL1282035 | 0.85 | OPRM1 (0.38) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL16909659 | 0.85 | OPRM1 (0.37) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL16909789 | 0.84 | RET (0.44) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL15579197 | 0.78 | DGAT1 (0.38) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL15578123 | 0.77 | KIT (0.48) | OPRM1 | |
| SCHEMBL16909568 | 0.77 | CYP3A4 (0.40) | KDM4EPOLBRIPK1 | |
| SCHEMBL17202032 | 0.75 | TRPV3 (0.40) | ADRA1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872508-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2018-08-29 | — | — | EP | disclosed |
| US-9309243-B2 | Imidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2016-04-12 | — | — | US | disclosed |
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | UCB Biopharma SPRL a corporation | 2015-07-23 | — | — | US | disclosed |
| EP-2872508-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014009295-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, IL1A | OPRM1 572/4885OPRD1 137/4885OPRK1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.